According to revealed studies, the activation of TGF-β promotes the EMT response, which is not only the downregulation of epithelial markers such as E-cadherin, but also the upregulation of mesenchymal markers including N-cadherin, α-SMA, and vimentin following tumor progression [52,53]. The gene discussed is TGFB1; the disease is neoplasm.